Excerpt from Wall Street Journal VC Daily Re-Vana, Boehringer Strike Deal for Gentler Eye-Disease Treatments By Brian Gormley, WSJ Pro Good day. Eye injections are a fact of life for many patients with severe ocular diseases. In a new partnership, Re-Vana...
The partnership strengthens the University’s reputation as a leading UK university for commercialisation of research and nurturing spin-outs capable of global impact. A spin-out from Queen's University – Re-Vana Therapeutics – has signed a major collaboration deal...
Up to three development programs per year leading to a potential total deal value exceeding $1 billion contingent on milestone achievements. Ingelheim, Germany, Tampa, Florida, USA, and Belfast, Northern Ireland, UK [28 July 2025] – Boehringer Ingelheim and Re-Vana...